Antibody-drug conjugates offers many advantages as a drug delivery platform that allows for highly specific targeting of cell types and genes. Ideally, testing the efficacy of these systems requires t

NIAID Data Ecosystem60

Table 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

抗体药物偶联物

卵巢癌模型

Cell lines with their demographics and characteristics for primary endometrioid cancers

NIAID Data Ecosystem40

Data from: Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models

结直肠癌靶向治疗

抗体药物偶联物

Colorectal cancer (CRC) remains the second-leading cause of cancer-associated deaths, indicating an urgent need for improved therapeutic options. We previously generated antibody-drug conjugates (ADCs

Mendeley Data60

Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate

抗体药物偶联物

肿瘤靶向治疗

Antibody drug conjugates (ADCs) are no longer an unknown entity in the field of cancer therapy with the success of marketed ADCs like ADCETRIS and KADCYLA and numerous others advancing through clinica

Figshare2017-05-31 更新50

The stability of linker-drug complexes 14 and 16 in PBS.

资源简介：

相关数据集